because there is av node in the heart that blocks most of the impulse from atria to ventricles.as for eg if there is 300 beats in atria then its blocks and it slow down the impulse so that there will be around 200 beats to ventricles.
during ventricular fibrillation there is not any such devices so it directly affects the system as a result bp increases etc that may lead to death.
Sanzay Maharzzan lzmc
Ventricular fibrillation, since this pumps blood to the rest of the body.
Most often, cardioversion is used to treat atrial fibrillation or atrial flutter. Life-saving cardioversion can be used to treat ventricular tachycardia and ventricular fibrillation.
Atrial Fibrillation, Ventricular tachycardia, Ventricular fibrillation, Supraventricular tachycardia
Defibrillation is performed to correct life-threatening arrhythmias of the heart including ventricular fibrillation and cardiac arrest.in non-life threatening situations, atrial defibrillation can be used to treat atrial fibrillation or flutter.
Ventricular fibrillation is more serious than atrial fibrillation because it can lead to cardiac arrest and sudden death if not treated immediately. Atrial fibrillation, while still a serious condition, is generally less life-threatening than ventricular fibrillation.
They're he same thing. Atrial flutter is more of a slang term, and is sometimes found in patients with atrial tachycardia. Basically, atrial fibrillation is a disorder, and atrial flutter is a symptom
Amiodarone is primarily used to treat ventricular dysrhythmias, particularly ventricular tachycardia (VT) and ventricular fibrillation (VF). It is also effective in managing atrial fibrillation and atrial flutter, especially in patients with heart failure or structural heart disease. The drug works by prolonging the action potential and refractory period in cardiac tissues, helping to restore normal rhythm.
Atrial Flutter. You may be thinking of atrial fibrillation, though.
120
Ventricular
these arrhythmias can cause a blood clot to form in the heart. This can lead to a stroke or a blockage carried by the blood flow (an embolism ) anywhere in the body's arteries. Atrial fibrillation is responsible for about 15% of strokes
Azimilide is currently being evaluated for its use in atrial fibrillation, atrial flutter, and PSVT. Additionally there were phase III trials being conducted for ventricular tachyarrhythmias and in patients with ICDs. The drug has not yet been approved by the FDA and thus has no labeled indications at this time.